BETRF (BetterLife Pharma) ROCE % : 0.00% (As of Jul. 2024)

View and export this data going back to 2010. Start your Free Trial

What is BetterLife Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BetterLife Pharma's annualized ROCE % for the quarter that ended in Jul. 2024 was 0.00%.

BetterLife Pharma ROCE % Historical Data

The historical data trend for BetterLife Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma ROCE % Chart

BetterLife Pharma Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

ROCE %

Get a 7-Day Free Trial

-316.19

-2,785.26

BetterLife Pharma Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

BetterLife Pharma ROCE % Calculation

BetterLife Pharma's annualized ROCE % for the fiscal year that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jan. 2024 )		(A: Jan. 2023 )		(A: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jan. 2024 )		(A: Jan. 2023 )		(A: Jan. 2024 )
	=	-2.122	/	( ( (0.056 - 5.325)	+	(0.242 - 5.086) )	/ 2 )
	=	-2.122	/	( (-5.269	+	-4.844)	/ 2 )
	=	-2.122	/	-5.0565
	=	41.97 %

BetterLife Pharma's ROCE % of for the quarter that ended in Jul. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jul. 2024 )		(Q: Apr. 2024 )		(Q: Jul. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jul. 2024 )		(Q: Apr. 2024 )		(Q: Jul. 2024 )
	=	-3.608	/	( ( (0.58 - 4.663)	+	(0.328 - 4.564) )	/ 2 )
	=	-3.608	/	( ( -4.083	+	-4.236 )	/ 2 )
	=	-3.608	/	-4.1595
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Jul. 2024) EBIT data.

BetterLife Pharma (OTCPK:BETRF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BetterLife Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (OTCPK:BETRF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NPAU:Germany BETR:Canada

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

Executives

Barbara-jean Anne Bormann-kennedy	director, officer: President	1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Moira Ong	officer: Chief Financial Officer	2392 LAWSON AVENUE, WEST VANCOUVER A1 V7V 2E6
Hassan Salari	director, 10 percent owner	1517 WEST 58TH AVENUE, VANCOUVER A1 V6P 1W6
Ahmad Doroudian	director, officer: Chairman	1275 WEST 6TH AVENUE, VANCOUVER A1 V6H 1A6